Literature DB >> 1643940

Variable severity of pulmonary disease in adults with identical cystic fibrosis mutations.

W Burke1, M L Aitken, S H Chen, C R Scott.   

Abstract

Adults with CF followed in a university center were assessed for the presence of the most common CF gene mutation, delta-F508. Excluding one member of a sibling pair, 29 of 55 subjects had two copies of delta-F508 (homozygotes), 23 had one copy of delta-F508 with the other CF mutation not identified (complex heterozygotes) and three were lacking delta-F508. A wide range of clinical severity was seen among individuals carrying two copies of the delta-F508 gene, who are genetically identical at the CF gene locus. The number of individuals diagnosed with CF as adults was significantly lower in the homozygote group (1 of 29) as compared with the heterozygote group (7 of 24). No differences were detected between groups in pulmonary function, non-pulmonary complications or overall clinical severity. These results suggest that environmental or background genetic factors contribute significantly to the variability in pulmonary and other complications seen among individuals with CF.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1643940     DOI: 10.1378/chest.102.2.506

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  8 in total

1.  Genetics through a primary care lens.

Authors:  L Pinsky; R Pagon; W Burke
Journal:  West J Med       Date:  2001-07

2.  PCR-analyzed microsatellites for the inbred mouse strain 129/Sv, the strain most commonly used in gene knockout technology.

Authors:  C Matouk; D Gosselin; D Malo; E Skamene; D Radzioch
Journal:  Mamm Genome       Date:  1996-08       Impact factor: 2.957

3.  Variants in the glutamate-cysteine-ligase gene are associated with cystic fibrosis lung disease.

Authors:  Edward F McKone; Jing Shao; Daisy D Frangolias; Cassie L Keener; Cynthia A Shephard; Federico M Farin; Mark R Tonelli; Peter D Pare; Andrew J Sandford; Moira L Aitken; Terrance J Kavanagh
Journal:  Am J Respir Crit Care Med       Date:  2006-05-11       Impact factor: 21.405

Review 4.  Mucosal Immunity in Cystic Fibrosis.

Authors:  Christine M Bojanowski; Shiping Lu; Jay K Kolls
Journal:  J Immunol       Date:  2021-12-15       Impact factor: 5.426

Review 5.  Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice.

Authors:  C Castellani; H Cuppens; M Macek; J J Cassiman; E Kerem; P Durie; E Tullis; B M Assael; C Bombieri; A Brown; T Casals; M Claustres; G R Cutting; E Dequeker; J Dodge; I Doull; P Farrell; C Ferec; E Girodon; M Johannesson; B Kerem; M Knowles; A Munck; P F Pignatti; D Radojkovic; P Rizzotti; M Schwarz; M Stuhrmann; M Tzetis; J Zielenski; J S Elborn
Journal:  J Cyst Fibros       Date:  2008-05       Impact factor: 5.482

6.  Interaction between a novel TGFB1 haplotype and CFTR genotype is associated with improved lung function in cystic fibrosis.

Authors:  Lindsay A Bremer; Scott M Blackman; Lori L Vanscoy; Kathryn E McDougal; Amanda Bowers; Kathleen M Naughton; David J Cutler; Garry R Cutting
Journal:  Hum Mol Genet       Date:  2008-04-17       Impact factor: 6.150

7.  Genetic and clinical features of patients with cystic fibrosis diagnosed after the age of 16 years.

Authors:  K H Gan; W P Geus; W Bakker; C B Lamers; H G Heijerman
Journal:  Thorax       Date:  1995-12       Impact factor: 9.139

Review 8.  The Impact of Air Pollution on the Course of Cystic Fibrosis: A Review.

Authors:  Marion Blayac; Patrice Coll; Valérie Urbach; Pascale Fanen; Ralph Epaud; Sophie Lanone
Journal:  Front Physiol       Date:  2022-06-02       Impact factor: 4.755

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.